-
Mashup Score: 16Post-ASCO & ESMO GI 2025 Highlights Archives - VJOncology - 6 day(s) ago
We use cookies to provide the b est experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie
Source: www.vjoncology.comCategories: General Medicine NewsTweet
-
Mashup Score: 0What are some remaining challenges in testicular cancer? - 6 day(s) ago
Ciara Conduit, FRACP, MBBS, PGCert MEd, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses unmet needs in testicular cancer, including mental health issues such as stress and anxiety as a result of diagnosis. More support is required for patients who need it, especially when suicide rates are higher in this population. Novel biomarkers such as microRNAs (miRNAs) are additionally under investigation, where they will be useful for patients who have tumors that may not be able to be easily biopsied. This interview took place at the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group annual scientific meeting in Melbourne, Australia. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet-
April is #TesticularCancerAwarenessMonth 📣 And we are passionate about bringing you the latest news & updates 🎥 🗞️ @ciaraconduit, discusses unmet needs in #testicularcancer, including #stress and #anxiety as a result of diagnosis💡 👉 https://t.co/qNErKOLZ8K
-
-
Mashup Score: 0
Alessandro Bertini, MD, IRCCS Ospedale San Raffaele, Milan, Italy & Henry Ford Health System, Detroit, MI, describes a multicenter propensity score-matched analysis comparing perioperative outcomes of single-port (SP) and multi-port (MP) robotic-assisted radical prostatectomy (RALP). Findings suggest that SP-RALP is associated with shorter operative time, and decreased length of stay, though it has a higher rate of positive surgical margins. No significant differences were observed in postoperative complications. This interview took place at the 2025 European Association of Urology (EAU) Congress in Madrid, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine NewsTweet-
🎥Alessandro Bertini, MD, shares findings from a study comparing SP vs MP robotic-assisted prostatectomy. SP-RALP shows shorter operative time but higher positive margin rates: ➡️https://t.co/zRqCOUeieZ⬅️ #EAU25 #UroOnc #UroSoME #PCSM #SurgOnc
-
-
Mashup Score: 1
Mike Sathekge, MBChB, University of Pretoria, Pretoria, South Africa, comments on the accessibility of the latest theranostics, which are currently limited to the affluent, but emphasizes the need to make them affordable and accessible to all. The current approval and trial landscape disproportionately benefits high-income countries, excluding low and middle-income countries from participating in these technologies. This interview took place at the 2025 European Association of Urology (EAU) Congress in Madrid, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine NewsTweet-
🎥Prof. Mike Sathekge from @UPTuks highlights the need to make theranostics accessible to all, noting that current trials and approvals mainly benefit high-income countries, excluding others: ➡️https://t.co/AWtm3KT0DO⬅️ #EAU25 #UroOnc #UroSoMe
-
-
Mashup Score: 3What is the role of surgery is in pleural mesothelioma? - 7 day(s) ago
Isabelle Schmitt-Opitz, MD, University Hospital Zurich, Zurich, Switzerland, emphasizes the potential role of surgery in early-stage mesothelioma, particularly in epithelioid subtypes. Despite results from the MARS 2 trial (NCT02040272), surgery should not be entirely ruled out from the treatment landscape, but current biomarkers may not be sufficient to identify patients best suited for surgery. This interview took place at the European Lung Cancer Congress (ELCC) 2025 in Paris, France. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine NewsTweet-
🎥at #ELCC25 @IsaOpitz from @ThoracicZurich underscores that surgery still has a role in early-stage epithelioid #mesothelioma. Despite MARS 2 results, better biomarkers are needed to guide patient selection: ➡️https://t.co/WURWyLfB0H⬅️ @myESMO #LungCancer #LCSM
-
-
Mashup Score: 0
Peter Albers, German Cancer Research Center (DKFZ), Heidelberg & Heinrich-Heine-University, Düsseldorf, Germany, comments on the PROBASE trial of risk adapted screening for prostate cancer and its findings. Men who have been biopsied with a negative finding are unlikely to develop prostate cancer in the next five years and duplicating PSA values are important to reduce the high-risk group that needs diagnosis. This interview took place at the 2025 European Association of Urology (EAU) Congress in Madrid, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine NewsTweet-
🎥Prof. Peter Albers of @DKFZ ighlights #PROBASE trial insights: men with negative biopsies have low 5-year risk of #ProstateCancer. Duplicating PSA values helps refine high-risk groups: ➡️https://t.co/91XlrRFbid⬅️ #EAU25 #UroOnc #UroSoMe #PCSM
-
-
Mashup Score: 1
Giannis Mountzios, MD, Henry Dunant Hospital, Athens, Greece, gives an overview of the Y-LUNG initiative, which aims to elucidate the mechanisms of carcinogenesis in young patients with lung cancer, particularly those under 45 years old, who often have never smoked and are not exposed to known environmental carcinogens. The initiative will investigate environmental, genetic, and occupational factors contributing to this trend. This interview took place at the European Lung Cancer Congress (ELCC) 2025 in Paris, France. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine NewsTweet-
🎥Giannis Mountzios (@g_mountzios) of @HenryDunantMD introduces the Y-LUNG initiative—exploring why #lungcancer affects patients <45 with no smoking or environmental exposure. Focus: genetic, environmental & occupational factors ➡️https://t.co/9uCq3oqvQb⬅️ @myESMO #ELCC25 #LCSM
-
-
Mashup Score: 0
David Baldwin, MD, FRCP, Nottingham City Hospital, Nottingham, United Kingdom, provides an overview of barriers to lung cancer screening in clinical trials and the real-world. Practical barriers, such as cost and comorbidities, as well as psychological barriers related to the potential diagnosis, can hinder patient participation. Local, community-led programs, staffed by individuals who have personal experience with lung cancer, are crucial in overcoming these barriers and achieving high uptake rates, as seen in the UK’s lung screening program. This interview took place at the European Lung Cancer Congress (ELCC) 2025 in Paris, France. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet-
🎥David Baldwin (@DRBLUNGS) of @nottmhospitals highlights barriers to #lungcancer screening—costs, comorbidities & fear of diagnosis. Community-led programs with lived experience boost uptake in the UK: ➡️https://t.co/sAx7CVa8gL⬅️ @myESMO #ELCC25 #LCSM
-
-
Mashup Score: 3Adjuvant/neoadjuvant treatment of cutaneous SCC - 9 day(s) ago
Vishal Patel, MD, FAAD, FACMS, George Washington University (GW), Washington, DC, comments on the shifting paradigm in treating locally advanced cutaneous squamous cell carcinoma (SCC), highlighting the evolution from surgical therapy to immunotherapy, with impressive results from pivotal trials and promising data on adjuvant immunotherapy, leading to significantly improved outcomes. This interview took place at the 11th World Congress of Melanoma and 21st EADO Congress in Athens, Greece. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet-
🎥Vishal Patel, MD, FAAD, FACMS, of @GWSMHS, highlights the shift from surgery to immunotherapy in advanced cutaneous SCC—driven by strong trial data & adjuvant advances improving patient outcomes: ➡️https://t.co/RhUl9VOzKM⬅️ #Melanoma2025 #EADO2025 #Skcsm #ImmunoOnc
-
-
Mashup Score: 0The impact of durvalumab on the SCLC treatment landscape - 10 day(s) ago
Suresh Senan, MRCP, FRCR, PhD, Amsterdam University Medical Centers, Amsterdam, Netherlands, comments on the current status of durvalumab in the treatment of small cell lung cancer (SCLC). Durvalumab has obtained global regulatory approval following the ADRIATIC trial (NCT03703297), but the NRG-LU005 (NCT03811002) showed that concurrent immunotherapy and chemoradiotherapy was not as efficacious. Further trials are need to determine the optimal timing and approach of immunotherapy, including sequential and concurrent regimens, to establish the best standard of care for this patient population. This interview took place at the European Lung Cancer Congress (ELCC) 2025 in Paris, France. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine NewsTweet-
🎥At #ELCC25, Suresh Senan, PhD, discusses durvalumab in #SCLC: approved post-ADRIATIC, but NRG-LU005 showed limited benefit with concurrent use. More trials needed to optimize timing & regimen: ➡️https://t.co/W7QmcYRJgm⬅️ @myESMO #LCSM #LungCancer #ImmunoOnc #TrialUpdate #CTSM
-
Catch up on the latest breakthroughs in #Oncology with our expert-led Post-#ASCO2025 & #ESMOGI Highlights webinars💻📍@ASCO @myESMO Charied by @evaciruelos @NReguart Dr. Neera Agarwal @MeredithMcKean @LorenzaRimassa REGISTER 👉 https://t.co/0cOqvDUdvf https://t.co/oCjLBXCQmk